Lonza expands services in China
This article was originally published in Scrip
The contract pharmaceuticals and chemicals manufacturer Lonzahas set up a new business unit in China to provide a range of engineering, facility design and maintenance services. The operation would initially service the life sciences sector in the country but might eventually expand to the other markets, the Swiss firm said. Lonza opened a small-scale synthesis facility in China last year as part of a continued build-up in the country.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.